FDA/CMS Collaboration: “Sleeper Group” Goes Public With Call For Real-World Evidence
US FDA, CMS and NIH are hoping to create a “single front door” for research. Article outlining collaboration on real-world evidence suggests one path forward.
You may also be interested in...
Officials are enthusiastic about the possibility of ‘real world evidence’ supporting the regulatory process – but are also eager to tamp down expectations (or fears) that it will make a big difference any time soon.
Acting Administrator Slavitt says big prescription drug price increases are a widespread practice and controlling drug costs ‘is likely to be a big priority’ for next head of CMS.
The Sentinel post-marketing surveillance system is up and running. Now, FDA is ready to explore uses beyond safety.